Exelixis | EXEL - L'Utile Ante Imposte





L'Utile Ante Imposte Cambiamento Data
Acadia Pharmaceuticals USD 46.47M 42.49M 2026-06
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Akebia Therapeutics USD -11.24M 12.39M 2025-12
Amgen USD 2.08B 570M 2026-03
AstraZeneca USD 4.81B 894M 2026-06
Bayer EUR 321M 2.67B 2026-06
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Bristol-Myers Squibb USD 4.99B 1.75B 2026-06
Cytokinetics USD -206.03M 23M 2026-03
Eisai JPY 25.28B 33.22B 2026-06
Eli Lilly USD 8.85B 583.8M 2026-03
Exelixis USD 262.68M 5.01M 2026-06
Genmab DKK 295M 221M 2026-06
Glaxosmithkline GBP 2.14B 312M 2026-03
Incyte USD 751.51M 407.91M 2026-06
Ionis Pharmaceuticals USD -114M 21M 2026-06
MacroGenics USD -36.77M 21.84M 2026-03
Merck USD -3.53B 6.95B 2026-03
Moderna USD -1.33B 535M 2026-03
Nektar Therapeutics USD -43.09M 8.39M 2026-03
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Novartis USD 4.27B 430M 2026-06
Pfizer USD -653M 5.84B 2026-06
Puma Biotechnology USD 20.61M 24.76M 2024-09
Sanofi EUR 2B 3.16B 2026-03
Takeda JPY 162.72B 215.2B 2026-06
Ultragenyx Pharmaceutical USD -91M 93M 2026-06
Xencor USD -21.92M 106.72M 2026-06